title: Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.
abstract: BACKGROUND
  Sleep complaints are common in patients with major depressive disorder (MDD). Both MDD and antidepressant drugs characteristically alter objective sleep measures. This study compares the effects of mirtazapine and fluoxetine on sleep continuity measures in DSM-IV MDD patients with insomnia.
  
  
  METHODS
  Patients (N = 19) received initial baseline polysomnography evaluations over 2 consecutive nights. Subjects were randomly assigned to either fluoxetine (20-40 mg/day) or mirtazapine (15-45 mg/day) treatment for an 8-week, double-blind, double-dummy treatment trial. Single-night polysomnograms were conducted at weeks 1, 2, and 8, with depression ratings assessed at baseline and weeks 1, 2, 3, 4, 6, and 8. Statistical analysis was performed by repeated-measures analysis of variance followed by Dunnet's post hoc analyses.
  
  
  RESULTS
  Patients receiving mirtazapine (N = 8) had significant improvement in objective sleep physiology measures at 8 weeks. Improvements in sleep latency, sleep efficiency, and wake after sleep onset were significant after only 2 weeks of mirtazapine treatment. No significant changes in sleep continuity measures were observed in the fluoxetine group (N = 11). Both groups improved clinically in mood and subjective sleep measures from baseline, with no differences between groups.
  
  
  CONCLUSIONS
  These data demonstrate the differential effects of mirtazapine and fluoxetine, with significant improvement in favor of mirtazapine, on objective sleep parameters in MDD patients with insomnia.
authors.affiliation: Neuropsychopharmacology Treatment, Research, and Training Center, Department of Psychiatry, University of Connecticut Health Center, Talcott Notch Road, Farmington, CT 06030-6415, USA. winokur@psychiatry.uchc.edu
authors.forename: Andrew
authors.initials: A
authors.lastname: Winokur
authors.forename: Nicholas A
authors.initials: NA
authors.lastname: DeMartinis
authors.forename: Daniel P
authors.initials: DP
authors.lastname: McNally
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Gary
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Cormier
authors.forename: Keith A
authors.initials: KA
authors.lastname: Gary
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008803:Mianserin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008875:Middle Aged; D000078785:Mirtazapine; D017286:Polysomnography; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D005473:Fluoxetine; D008803:Mianserin; D000078785:Mirtazapine